Evaluaion of tolerability and efficacy of Melatrance lightening cream for the treatment of melasma
Phase 2
Recruiting
- Conditions
- Melasma.ChloasmaL81.1
- Registration Number
- IRCT20190210042676N25
- Lead Sponsor
- Knowledge-based company of Janus
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
18 - 50 years old men and women
Cases of mild to moderate melasma (MGSC=1& 2)
General health
Signing the consent form for participation in the study
Exclusion Criteria
Documented allergies to components of cream
Use of topical lightening products like AHA ,BHA and retinoid component within 21 days prior to the study
Pregnancy or lactating
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Modified melasma severity index. Timepoint: Before intervention, 6 weeks later and 12 weeks after intervention. Method of measurement: Using mMASI index.
- Secondary Outcome Measures
Name Time Method Skin melanin content changes. Timepoint: Before intervention,6 and 12 weeks after using. Method of measurement: mexameter.;Size and amount of skin spots. Timepoint: Before intervention, 6 and 12 weeks after using. Method of measurement: Visio face.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does Melatrance cream target to reduce melanogenesis in melasma (L81.1)?
How does Melatrance's efficacy in phase II trials compare to standard-of-care agents like hydroquinone for mild to moderate melasma?
Are there specific biomarkers, such as tyrosinase activity or melanocyte density, predictive of Melatrance response in melasma patients?
What adverse events are reported in phase II studies of Melatrance, and how do they compare to corticosteroid-based treatments for chloasma?
What combination therapies or alternative tyrosinase inhibitors are being evaluated alongside Melatrance for melasma treatment by Janus Pharmaceuticals?